Constance Keyserling
Chief Operating Officer at ABIONYX PHARMA
Profile
Constance Keyserling is currently the Director of Clinical Development & Operations at ABIONYX Pharma SA. Previously, she held positions as the Senior Director of Operations at Esperion Therapeutics, Inc., Manager of Clinical Research Operations at Pfizer Inc., Vice President of Development Operations at QuatRx Pharmaceuticals Co., and Manager of Clinical Research Operations at Parke, Davis & Co. LLC.
She obtained her graduate degree from Harvard University in 1984.
Constance Keyserling active positions
Companies | Position | Start |
---|---|---|
ABIONYX PHARMA | Chief Operating Officer | - |
Former positions of Constance Keyserling
Companies | Position | End |
---|---|---|
PFIZER, INC. | Corporate Officer/Principal | - |
ESPERION THERAPEUTICS, INC. | Chief Operating Officer | - |
Parke, Davis & Co. LLC | Corporate Officer/Principal | - |
QuatRx Pharmaceuticals Co.
QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | Corporate Officer/Principal | - |
Training of Constance Keyserling
Harvard University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
ABIONYX PHARMA | Health Technology |
ESPERION THERAPEUTICS, INC. | Health Technology |
PFIZER, INC. | Health Technology |
Private companies | 2 |
---|---|
QuatRx Pharmaceuticals Co.
QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | Health Technology |
Parke, Davis & Co. LLC |
- Stock Market
- Insiders
- Constance Keyserling